Enhanced osseointegration by the chemotactic activity of plasma fibronectin for cellular fibronectin positive cells. by Jimbo Ryo et al.
Biomaterials 
Original Article 
Title: Enhanced Osseointegration by the Chemotactic Activity of Plasma Fibronectin 
for Cellular Fibronectin Positive Cells 
Authors: Ryo Jimboa,1, Takashi Sawasea,1, Yasuaki Shibatab,*, Kazunari Hiratac, 
Yoshitaka Hishikawad, Yasuhiro Tanakae, Kazuhisa Besshof, Tohru Ikedab and Mitsuru 
Atsutaa 
Authors’ affiliations: 
aDivision of Applied Prosthodontics, Nagasaki University Graduate School of 
Biomedical Sciences, Nagasaki, Japan 
bDivision of Oral Pathology and Bone Metabolism, Nagasaki University Graduate 
School of Biomedical Sciences, Nagasaki, Japan 
cDivision of Oral and Maxillofacial Surgery, Nagasaki University Graduate School of 
Biomedical Sciences, Nagasaki, Japan 
dDivision of Histology and Cell Biology, Nagasaki University Graduate School of 
Biomedical Sciences, Nagasaki, Japan 
eDepartment of Advanced Materials Science, Faculty of Engineering, Kagawa 
University, Kagawa, Japan 
fDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto 
University, Kyoto, Japan 
1 Equally contributed to the experimental work. 
 
*Reprint requests and corresponding author: Yasuaki Shibata, Division of Oral 
Pathology and Bone Metabolism, Nagasaki University Graduate School of Biomedical 
Sciences, Nagasaki, Japan Tel: +81 95 849 7646, Fax: +81 95 849 7647,  
email: siva@nagasaki-u.ac.jp 
 
Funding Sources: This study was supported by a Grant-in-Aid for Exploratory 
Research (17659616). 
 














Abstract: Plasma FN (pFN) is known to regulate cell growth, differentiation or survival 
of osteoblasts in vitro. It is also speculated to be important for the early phase of 
osseointegration, however its actual in vivo behavior is unknown. The objective of this 
study is to clarify the role of pFN during osseointegration. We developed a titanium 
ion-plated acrylic implant (Ti-acryl) for thin sectioning without removal of the implant. 
Either Ti-acryl or pFN-coated Ti-acryl (FN-Ti-acryl) was implanted in the mouse femur. 
Samples were taken on day 1 to day 7 and on day 14 after the operation, and were 
decalcified and paraffin embedded. The bone healing process and immunofluorescence 
localization of pFN and cellular fibronectin (cFN), a marker for fibroblastic cells were 
examined. Simultaneously, the effect of pFN on chemotaxis, proliferation and 
differentiation of bone marrow stromal cells (BMSCs) was analyzed in vitro. The in 
vivo results showed that faster direct bone formation was seen for the FN-Ti-acryl group 
compared to the Ti-acryl group. The in vitro results showed that, pFN significantly 
promoted BMSCs chemotaxis, however had no effect on proliferation or differentiation. 
The results indicate that pFN regulated chemotaxis of osteogenic cells and coating the 
implant with pFN enhanced earlier osseointegration. 
 






The faster acquisition of the direct bone to implant anchorage, or so-called 
osseointegration, is the key factor in the faster functional loading of the implant. 
Comprehensive efforts and strategies have enhanced osseointegration for increased 
implant stability [1,2]. For example, the modification of the physical characteristics of 
the implant by sandblasting or chemical treatment of the implant surface has remarkably 
improved osseointegration as compared to turned surfaces [3-5]. The reason for such 
improvement is speculated to be the enhanced adsorption of native blood proteins, such 
as plasma fibronectin (pFN), onto the implant surface, which enhanced the formation of 
focal adhesions by osteoblasts through integrin-mediated mechanisms [6,7]. 
 
Plasma FN is a prominent extracellular matrix protein [8], which accumulates in the 
matrix during the early phase of cell growth and attachment [9]. Cellular FN (cFN), an 
another type of FN, is an insoluble form generated as a result of alternative splicing 
from a single gene [10]. It is expressed locally by certain fibroblastic cells and other cell 
types, and is deposited and assembled into the extracellular matrix [11].  It has been 
suggested that pFN activates the signaling pathways which direct cell-cycle progression, 
gene expression and matrix mineralization [12], and even regulating the survival of 
osteoblasts [13]. In fact, coating biomaterial surfaces with pFN in vitro has been shown 
to enhance the formation of focal adhesions by osteoblasts [14] and lead to better cell 
spreading and cytoskeleton organization compared to non-coated surfaces [15-17]. In 
addition, it has been reported that pFN adsorbed onto the implant surface when the 
implant was inserted in the abdominal walls of rats [18]. This evidence suggests that the 
pFN adsorbed onto the implant surface regulates cellular adhesion and consequent 
osseointegration. Park et al. have reported that early blood cell/implant interactions 
which leads to plasma protein accumulation may play a key role in the osteoconduction 
stage of osseointegration [19]. Rupp et al. have discussed the possible FN adsorption 
onto endosseous implants via the patient’s blood during surgery [20]. However, these 
reports were only speculations, and the actual behavior of FN at the molecular level in 
vivo around implants during the process of osseointegration remains uncertain. One of 
the reasons for this is the difficulty in making thin sections without the removal of the 
implant incorporated into the surrounding bone. Hence, most of the past studies were 
performed on undecalcified ground sections. Nevertheless, the ground sections clarified 
the osteoconductive bone regeneration process around the implants histologically and 
histomorphometrically [21,22], they did not allow for analysis at the molecular level.  
 
We developed an implant coated with a thin film of titanium by means of the ion-plating 
method [23]. With this implant, the preparation of paraffin-embedded or frozen sections 
for immunohistochemistry or in situ hybridization is possible without removing the 
titanium implant. In the current study, by using this implant, the effects of pFN on the 
osseointegration process in the mice femur histologically and histomorphometrically 
was examined, followed by immunofluorescence observation with pFN antibody and 
cFN antibody. Simultaneously, the effect of pFN on bone marrow stromal cells 
(BMSCs) was examined in the in vitro studies. 
2. Materials and Methods 
2.1. Fabrication of the titanium-ion-plated acrylic implant 
An acrylic rod (1.0 mm in diameter and 2.0 mm in length) was ultrasonically cleaned in 
ethanol and distilled water. The titanium-ion-plating methods were applied, based on 
our previous study [23]. Briefly, the specimens were placed for 10 minutes in an 
ion-plating apparatus (MODEL 1602EB; Ayers Rock Corp., Kanagawa, Japan) and 
were exposed to an argon gas plasma created under 100 W radio frequency power, 
12-16 mPa argon gas pressure and 500 V bias voltage. The thickness of the plated 
titanium was fixed to approximately 20 nm and was confirmed by a cross sectional 
transmission electron microscope (JEM 3010; JEOL) at an accelerating voltage of 300 
kV.  
 
2.2. Surgical procedures 
Ddy mice (8-week-old males, n=3) were anesthetized, a round bone defect 1.0 mm in 
diameter was created in the middle portion of the diaphysis of the left femur and the 
implants were inserted. The following two types of implants were used in the 
experiment:  
1. Ti-acryl (control group): titanium-ion-plated acrylic implant; 
2. FN-Ti-acryl (experimental group): titanium-ion-plated acrylic implant soaked in 
mouse plasma fibronectin (Biogenesis; concentration: 100 µg/ml) at 4 C˚ for 30 
minutes.  
 
The animals were sacrificed at 1, 2, 3, 4, 5, 7 and 14 days after the operation, the 
samples were perfusion-fixed with 4% paraformaldehyde (PFA) in phosphate-buffered 
saline (PBS), decalcified with 10% ethylenediaminotetraacetic acid and embedded in 
paraffin, and thin paraffin sections were prepared (thickness: 3 µm). The sections were 
first observed histologically with hematoxylin and eosin (H&E) staining. 
 
Animal care and experimental procedures were performed in accordance with the 
Guidelines for Animal Experimentation of Nagasaki University with the approval of the 
Institutional Animal Care and Use Committee.  
 
2.3. Immunofluorescence staining and in situ hybridization 
For the immunofluorescence staining, we prepared a rabbit anti-human pFN antibody 
according to the methods of Weiss et al. [24]. Additionally, as a marker for the 
fibroblastic cells, we used goat anti-human cFN antibody (C-20; Santa Cruz 
Biotechnology). The deparaffinized sections were first blocked with 1% bovine serum 
albumin (BSA) in PBS for 30 minutes at room temperature. The slides were incubated 
with the two primary antibodies diluted with PBS (1:200) for 2 hours at room 
temperature. After extensive washing with PBS, they were incubated with anti-rabbit 
fluorescein-linked whole antibody (GE Healthcare) and anti-goat Alexa Fluor 594 
(Molecular Probe). The fluorescence signals were visualized using a confocal laser 
microscope (LSM5 PASCAL; Carl Zeiss).    
 
In situ hybridization (ISH) was performed for both groups at day 4 in order to observe 
the osteogenic activity at the implant surface. For the probe preparation, the cDNAs of 
osteocalcin (Ocn) subcloned into pGEM-T Easy (Promega) were labeled with 
digoxigenin with either T7 or Sp6 RNA polymerase. The in situ hybridization was 
performed as described in our previous studies [25]. 
 
2.4. Histomorphometrical analysis 
The area of the implant surface that was in contact with bone (bone-implant contact, 
BIC) was calculated at days 5 to 14. The percentages of bone in direct contact to the 
implant surface were determined. 
 
The number of fibroblastic cells infiltrated around the implant was counted in a 
prescribed rectangular area for both groups (0.5 mm x 1.0 mm, adjacent to the implant 
surface). 
 
Histomorphometric analysis was performed on all specimens using an image analyzing 
software (Image J ver.1.36b; National Institutes of Health).  
 
2.5. Immunohistochemistry  
The proliferation activity of the fibroblastic cells around the implant at day 2 was 
analyzed by immunostaining the proliferating cell nuclear antigen (PCNA). After 
preincubation with 1% H2O2 in methanol for 30 minutes, and blocking with 1% BSA, 
the sections were incubated for 2 hours at room temperature with a 1:200 dilution of 
anti-PCNA antibody (PC10; DAKO). The sections were then incubated with the 
appropriate biotinylated secondary antibodies, followed by incubation with the 
avidin-biotin peroxidase complex (Vectastain Elite ABC kit; Vector). The peroxidase 
conjugates were subsequently localized using diaminobenzidine tetrahydrochloride as a 
substrate. The ratio of PCNA+ fibroblastic cells among all fibroblastic cells was 
calculated in a prescribed rectangular area (0.5 mm x 1.0 mm, adjacent to the implant 
surface).  
 
2.6. Cell culture  
The femurs and tibiae of the 8-week-old male ddy mice were cut at the epiphyses, and a 
BMSCs-rich fraction was obtained by flushing the diaphyseal channel with alpha-MEM 
(Gibco Laboratories) containing 10 % fetal calf serum, 100 µg/ml penicillin G and 100 
IU/ml streptomycin through a 23-gauge needle. The cells were then filtrated with a 
70-µm nylon filter (Cell Strainer; BD Bioscience), and cultured for 3 days in 
alpha-MEM containing 10 % FCS and antibiotics at 37 °C in 5 % CO2. After 3 days of 
primary culturing, the non-adherent population was aspirated and the adherent cells 
were collected by scraping with a rubber wiper; the adherent cells were then 
concentrated by centrifugation at 1500 revolutions per minute (rpm) for 5 minutes at 
room temperature and resuspended. 
2.7. Chemotaxis assay 
To examine whether or not pFN induces the chemotaxis of fibroblastic cells in the bone 
marrow, the chemotactic responses were measured by means of a modified Boyden 
chamber assay, using a 24-well-type chamber equipped with polycarbonate filters 
having 8-µm pores (Chemotaxicell-24; Kurabo, Kurashiki, Japan). The lower side of the 
filter was coated with either pFN or type-I collagen (ColI; Cell Matrix, Nitta-Gelatin, 
Osaka, Japan) for 30 minutes at room temperature within a wide concentration range 
(from 100 ng/ml to 100 µg/ml). A non-coated filter was used as a control. The lower 
wells were filled with 600 µl of alpha-MEM, and the upper wells were filled with the 
obtained cells (40 x 104 cells/ml) in 200 µl of medium. After 24 hours of incubation, the 
filters were carefully removed and the non-migrating cells on the upper side were 
eliminated by gentle scraping with a rubber wiper and rinsing with cold PBS. The 
migrating cells on the lower side of the filter were fixed with PFA and stained with 
toluidine blue. The number of migrating cells was counted at 10 x magnification, and 
the procedure was repeated in triplicate. 
 
2.8. In vitro proliferation assay 
The cellular proliferation activity was estimated based on the uptake of 
bromo-deoxyuridine (BrdU). Polystyrene 96-well plates were coated with pFN 
(concentration: from 100 ng/ml to 100 µg/ml) at 4 °C for 30 minutes. The wells were 
then blocked with 1% BSA for 30 minutes at room temperature and rinsed with PBS 
before adding the cells. As a control, ColI-coated wells with the same concentration 
range and non-treated wells were used. The cells were then added (40 x 104 cells/ml) 
and cultured for 24 hours. Cell viability was assessed by the BiotrakTM cell proliferation 
ELISA system (GE Healthcare), according to the manufacturer's instructions. 
 
2.9. Analysis of osteogenic differentiation in vitro 
In order to assess the osteoinductive role of pFN, BMSCs-rich fractions were cultured 
on pFN- or ColI-coated or non-coated dishes and transfected with adenoviral rh-BMP-2 
[26]. After 4 days, the transfection-elevated alkaline phosphatase (ALP) production was 
compared among the three groups. The ALP activity was detected by enzyme 
histochemistry, as in our previous studies [27].    
 
2.10. Statistical analysis 
All statistical analyses in this study were performed with KaleidaGraph (Synergy 
Software). The mean and standard deviation values of the histomorphometric and in 
vitro parameters (n=3) were calculated. The average values were compared by one-way 
analysis of variance, followed by a post hoc Tukey test with the value of statistical 
significance set at the 0.05 level. 
 
3. Results 
3.1. Histological examination of the bone formation process for Ti-acryl and 
FN-Ti-acryl  
In the Ti-acryl (control) group, the peri-implant bone healing proceeded as follows. At 
day 1, the peri-implant tissue was edematous (Fig. 1A). At day 2, a dense fibrin layer 
was observed just outside of the implant surface; sparse infiltration of spindle-shaped 
fibroblastic cells was noticed outside of the fibrin layer (Figs. 1B). At day 3, the 
fibroblastic cells surrounded the implant surface (Figs. 1C). At day 4, new bone 
formation was seen in an area hemmed by the cortex and the implant; however, bone 
formation could not be observed at the implant surface; mononuclear cells or 
fibroblastic cells surrounded the surface of the implant (Figs. 1D and 1E); no expression 
of Ocn mRNA was observed at the implant surface (Fig. 1F). At day 5, the bone volume 
increased; however, layers of fibroblastic cells were still observed at the implant surface 
(Fig. 1G). At day 7, the bone volume increased further and at last, the bone was in direct 
contact with the implant surface (Fig. 1H). At day 14, the bone volume increased even 
further and the bone became compact (data not shown).  
 
Whereas, in the FN-Ti-acryl (experimental) group, at day 1 the peri-implant tissue was 
less edematous than in the control group (Fig. 2A). At day 2, fibroblastic cells reached 
the implant surface and infiltrated the surrounding tissues (Figs. 2B). At day 3, a larger 
number of fibroblastic cells infiltrated the area around the implant compared to the 
Ti-acryl group (Fig. 2C). At day 4, deposition of bone matrix appeared directly on the 
implant surface, as well in an area hemmed by the cortex and the implant (Fig. 2D); 
osteoblastic cells rimming the matrix and osteocytic cells embedded in the matrix were 
observed under higher magnification (Figs. 2E and 2G); Ocn mRNA expression was 
detected in the cells at the bone-implant interface and in the bone matrix (Figs. 2F and 
2H). At day 5, the bone matrix was in direct contacted with the implant surface, without 
the intervention of any fibroblastic cells at the bone-implant interface, and the bone 
volume around the implant increased (Fig. 2I). At days 7 (Fig. 2J) to 14 (data not 
shown), the bone volume further increased and the bone became compact. 
 
3.2. Bone-implant contact analysis 
The BIC in the experimental group was significantly higher than those in the control 
group at day 5. In the control group, the BIC was 43.6 % and in the experimental group, 
the BIC was 81.6 %. There was no significant difference between the BIC values of 
these groups at days 7 and 14 (Figs 3A and 3B).  
 
3.3. Infiltration of fibroblastic cells and PCNA proliferation assay 
The total number of infiltrated fibroblastic cells in the experimental group was 1.86 
times larger than that in the control group (Fig. 3C). The percentage of PCNA+ 
fibroblastic cells at day 2 was 20.5 % in the control group and 19.2 % in the 
experimental group. (Fig. 3D) There was no significant difference in the proliferation 
rates of the two groups. 
 
3.4. Immunofluorescence staining  
In the control group at day 1, pFN signals were detected, not around the entire implant 
surface, but chiefly in an area hemmed by the cortex and the implant (Fig. 4A). At day 2, 
the pFN signals disappeared at the implant surface, whereas they could still be detected 
in the matrix away from the implant surface (Figs. 4B-4D). Strong cFN signals were 
detected in the fibroblastic cells; however, lower pFN signals were detected at the 
implant surface compared to the matrix away from the implant (Figs. 4C, 4E and 4F).  
The corresponding H&E stained sections show an infiltration of fibroblastic cells 
outside of the fibrin layer (Fig. 4G). At day 3, the pFN signals were drastically reduced 
(Fig. 4H) and the infiltration of cFN-negative fibroblastic cells could be seen at the 
implant surface (Figs. 4I-K). At day 4, both signals completely disappeared (data not 
shown). 
 
In the experimental group at day 1, pFN immunofluorescence signals were detected 
extensively around the implant surface and in the surrounding matrix (Fig. 5A). At day 
2, the pFN signals were still observable at the implant surface (Figs. 5B-5E); 
cellular-FN+ fibroblastic cells also reached the implant surface and infiltrated the 
surrounding matrix (Figs. 5C, 5E and 5F). The corresponding H&E sections show a 
direct infiltration of fibroblastic cells to the implant surface (Fig. 5G). At day 3, 
capillaries were generated in some places adjacent to the implant surface; the infiltration 
of cFN+ fibroblastic cells was also evident in this area (Figs. 5I-K), while pFN signals 
around the implant decreased (Fig. 5H). At day 4, both signals were still visible, but 




3.5. Effect of pFN on the chemotaxis, proliferation and osteo-differentiation of 
bone marrow stromal cells 
The chemotaxis assay revealed that pFN significantly promoted the chemotaxis of 
BMSCs compared to the ColI-coated or non-coated chambers (Fig. 6A). Although the 
chemotactic activity of BMSCs increased in a dose dependent manner in both the pFN 
and the ColI-coated group, the chemotactic ratio in the pFN-coated group was 
significantly higher than that in the ColI-coated group at all concentrations tested.  The 
BrdU-uptake of BMSCs cultured on the various groups of wells did not result in any 
significant differences in proliferation ratio (Fig. 6B). The histochemical analysis of the 
ALP enzyme revealed no drastic variance in ALP activity between any of the cells 
cultured on any well after the transfection of BMP-2 (Fig. 6C).   
 
4. Discussion 
This is the first report that addressed the in vivo localization and role of pFN during 
osseointegration. Our results demonstrated that coating the implant with pFN induced 
faster osseointegration compared to the non-coated implant, and suggested that this 
phenomenon was due to the recruitment of larger number of cFN+ BMSCs closer to the 
implant surface by the preferential chemotactic activity of pFN. Although the adsorption 
of blood proteins to the titanium implant has been suggested to play an important role 
for osseointegration [7,28], the actual in vivo localization of blood proteins and its role 
for osseointegration remained uncertain. In this study, we developed the 
paraffin-sectionable titanium ion-plated acrylic implant model for the detection of in 
situ localization of molecules involved in osseointegration. The paraffin sections 
showed titanium film attached directly to the periimplant tissue, meaning the 
bone-implant or tissue-implant interface was well preserved. 
 
During days 2-3, there was a drastic reduction of the pFN signal in the control group. In 
contrast, the pFN signal could still be detected at the implant surface in the experimental 
group. The pFN detected in the experimental group may be due to the release of pFN 
from the pFN coated implant. The histological results of this study show that, at day 2, 
the infiltration of a larger number of cFN+ BMSCs to the implant surface could be 
observed in the experimental group compared to the control group (Fig. 3C). At day 3, 
the infiltration of cFN+ BMSCs to the implant surface was evident only in the 
experimental group, and the cells which reached the implant surface in the control 
group were cFN-negative (Figs. 4I, K and 5I, K). In this study, cells with integrin 
receptors were speculated to migrate to the pFN accumulated implant surface, but the 
mechanisms of the preferential chemotaxis of the cFN+ BMSCs remained uncertain. 
However the results of this study indicated a close relationship between pFN and cFN+ 
BMSCs, as Hayman et al. have suggested [29] and furthermore, pFN was suggested to 
induce the preferential chemotaxis of cFN+ BMSCs. In addition, the histological results 
showed that the pFN-coated implant induced faster osseointegration. These results 
strongly suggest that the cFN+ BMSCs possess a higher tendency to differentiate into 
osteogenic cells.  
 
The prominent vasculogenesis around the experimental implant may also have been the 
result of the chemotactic activity of pFN, because mice lacking FN die around 
embryonic day 8.5 due to severe defects in mesodermally derived tissues, including 
defects of vasculogenesis [30]. As vascularization is reported to be indispensable for 
osseointegration [31], further vasculogenesis induced by the administration of pFN may 
also accelerate osseointegration. 
 
Osseointegration is defined as the direct anchorage of an implant due to the formation 
of bony tissue around the implant, without the growth of fibrous tissue at the 
bone-implant interface [31]. From the clinical point of view, during this process, two 
factors play an important role: primary stability (mechanical stability) and secondary 
stability (biological stability after bone remodeling) [32]. Primary stability is the 
mechanical stability of the implant as soon as the implant is placed into the bone. It 
gradually decreases in the bone remodeling process. Secondary stability is the contact of 
new bone with the implant after bone remodeling. Primary stability is fully replaced by 
secondary stability when the healing process is completed. However, at one point, the 
implant stability decreases during the stability conversion, a process also called the 
“dip”. Many implant failures occur during this period, and this period seems to be 
critical to the successful integration of the implant [33]. The results of this study suggest 
that the adsorption of pFN onto the implant surface advances the starting point of the 
achievement of secondary stability.  
 
Coating the implant with pFN significantly enhanced osseointegration at days 4 and 5, 
however the results of the BIC analysis showed that there was no significant difference 
between the two groups at days 7 and 14, which mark the latter stages of bone 
regeneration. These results imply that pFN may be an important factor for the initial 
stages of osseointegration which have a profound impact on the bone-implant stability. 
Hence, strategies to induce the adsorption of pFN onto the implant would accelerate 
osseointegration and substantially reduce the stability dip if a sufficient amount of pFN 
can be adsorbed. There are two possible strategies for the progressive adsorption of pFN 
onto the implant surface. One is to mechanically coat the implant with pFN, as done in 
this study. The other is to physico-chemically modify the implant surface in order to 
render it optimal for further accumulation of the endogenic pFN. Deligianni et al. have 
stated that higher amounts of FN were found on rough titanium surfaces compared to 
smoother surfaces [34]. The surface roughness of the model we used in this study was 
Ra=0.815, a relatively smooth surface, and the reduction of the pFN signal could be 
seen by day 2 in the control group. It may well be useful to roughen the surface not only 
to ensure the longer duration of pFN around the implant but also to enable the 
mechanical coating of the implant surface with a larger amount of pFN.  
 
The observed remarkable enhancement of new bone apposition on the pFN-coated 
implant surface during the initial stages of osseointegration is promising and could lead 
to a significant reduction of the healing period in clinical applications.  
 
5. Conclusion 
This current study using the newly developed titanium ion-plated acrylic implant 
experimental system showed that coating plasma fibronectin (pFN) onto the implant 
surface induced earlier osseointegration than that of the non-coated control.  In vitro 
chemotaxis assay showed chemotaxis of cellular fibronectin (cFN)-positive bone 
marrow stromal cells by the effect of pFN.  The in vivo and in vitro results suggested 
that adsorption of pFN onto the implant surface was effective for earlier 
osseointegration due to the release of pFN and for the subsequent chemotaxis of 
cFN-positive bone marrow stromal cells with an osteogenic potential. 
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